skip to Main Content

TB Drugs for Children

Poor treatment options spur innovative research strategies By Polly Clayden, HIV i-Base Pediatric Drug Development Considerations: Pharmacokinetics There is an old adage in pediatric medicine: children are not little adults. This is particularly true when it comes to tuberculosis, for…

Read more

The “G” Word

Gilead’s greed gives rise to a slew of advocacy priorities By Tracy Swan Activists are decrying Gilead’s refusal to continue codeveloping a winning HCV drug combination with Bristol-Myers Squibb (BMS), opting instead to focus on co-formulations of its own promising…

Read more

Ryan White at a Crossroads

Preparing to defend and reshape a still-critical program By Coco Jervis An increasing demand for services, coupled with significant fiscal retrenchment among federal and state agencies, leaves the Ryan White HIV/AIDS CARE Act-funded program at a crossroads. But advocacy strategies…

Read more

Advancing Research, Securing Access

By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…

Read more

TAGline Spring 2013

Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.
Read more

TB Zeroes Campaign Achieves Big Win

by Erica Lessem The world has recently called for zero new TB deaths, infections, and suffering, and that voice has been heard. Treatment Action Group (TAG), along with other activists, researchers, clinicians, implementers, policy makers, and foundation and government staff…

Read more

Data Deluge at AASLD

by Tracy Swan It is difficult not to be dazzled by cure rates of up to 100% from interferon-free hepatitis C virus (HCV) trials presented at the American Association for the Study of Liver Diseases (AASLD) meeting in November 2012.…

Read more
Back To Top